// App-Quantinova.ai

2359 : A-337, a potent bispecific antibody targeting EpCAMCD3, as a potential immunotherapeutic agent for human solid tumors

Researchers

Presenter

  • Yumin Cui

Principal Investigators

  • Zhihua Huang

  • Hanyang Chen

  • Xinfeng Zhang

  • Bo Qi

  • Heng Liu

  • Xiaoqiang Yan

Medical Centers

  • Generon (Shanghai) Corporation, Shanghai, China.

Locations

  • China

Companies

  • Generon (Shanghai) C

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 2AP

  • Cluster of differentiation 69

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved